Myelodysplastic Syndrome (Myelodysplastic Neoplasms, MDS): Disease Characteristics Research Report

Target Disease

• Disease name: Myelodysplastic Syndrome (WHO 2022 preferred: Myelodysplastic Neoplasms, abbreviated MDS) (lucero2023managementofpatients pages 1-2)
• Category: Clonal hematopoietic stem/progenitor cell myeloid neoplasm / bone marrow failure malignancy with variable risk of AML transformation (niscola2024latestinsightsand pages 1-2, thalla2025advancesandchallenges pages 1-2)
• ICD-10 (clinical coding commonly used): D46 (captured in GBD analyses covering ICD-10 D45–D47 and noted in MDS burden methods) (gou2025globalregionaland pages 2-3)
• MONDO / MeSH / Orphanet / OMIM IDs: Not directly retrievable with tool-backed evidence in this run; use external ontology sources to finalize identifiers.

1. Disease Information

1.1 Concise overview (current understanding)

MDS are heterogeneous clonal myeloid malignancies arising from hematopoietic stem cells, characterized by morphologic dysplasia, ineffective hematopoiesis, and resulting peripheral blood cytopenias with a variable propensity to progress to acute myeloid leukemia (AML) (thalla2025advancesandchallenges pages 1-2, lucero2023managementofpatients pages 1-2).

1.2 Common synonyms / alternative names

• Myelodysplastic syndromes (historical term) (lucero2023managementofpatients pages 1-2)
• Myelodysplastic neoplasms (WHO 2022 nomenclature) (lucero2023managementofpatients pages 1-2)
• “Preleukemic” bone marrow failure disorder (conceptual; progression risk emphasized in multiple reviews) (thalla2025advancesandchallenges pages 1-2)

1.3 Aggregated resources vs individual patients

The information below is derived from aggregated disease-level resources (reviews, registries, large cohorts, and randomized trials) rather than EHR-only case series (e.g., GBD analyses; registry-based classification validations; phase 3 trials) (zhang2022comparisonofthe pages 1-2, platzbecker2023…andsafety pages 1-2, gou2025globalregionaland pages 1-2).

2. Etiology

2.1 Disease causal factors (mechanistic, genetic, environmental)

MDS arises via multistep acquisition of somatic genetic lesions in hematopoietic stem/progenitor cells, producing clonal dominance, dysplasia, and marrow failure; the process is influenced by aging, immune/inflammatory microenvironmental changes, and selection pressures including genotoxic exposures (niscola2024latestinsightsand pages 1-2, karel2024myelodysplasticneoplasms(mds) pages 1-2, nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

2.2 Risk factors

2.2.1 Age and premalignant clonal states

• MDS commonly arises from antecedent clonal hematopoiesis states including CHIP and CCUS, which are detectable via genomic analysis and represent premalignant conditions in some individuals (niscola2024latestinsightsand pages 1-2).
• CHIP prevalence rises with age (≈10% by age ≥80 in one review), and CHIP confers an estimated ~0.5–1% per year risk of developing MDS (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

2.2.2 Therapy-related and genotoxic exposures

• Prior exposure to chemotherapy, radiotherapy, and radioiodine therapy is explicitly highlighted as an MDS risk factor in a 2023 clinical review (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• In clonal hematopoiesis literature, selection pressures promoting CH expansion and therapy-related myeloid neoplasms include chemotherapy agents (e.g., cisplatin, etoposide, doxorubicin) and radiation (zhang2024implicationsofclonal pages 2-4).

2.2.3 Smoking

Smoking is discussed as a selection pressure in CH biology and is associated with specific mutation patterns (e.g., association with ASXL1 mutations) (zhang2024implicationsofclonal pages 2-4).

2.2.4 Autoimmune/inflammatory comorbidity

Pre-existing autoimmune disease is reported in ~10–30% of MDS patients, and inflammatory pathway activation is implicated in pathogenesis (niscola2024latestinsightsand pages 1-2).

2.2.5 Germline predisposition

Germline predisposition is described as more frequent than previously recognized, particularly in younger adults (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

2.3 Protective factors

No tool-retrieved primary evidence identified specific protective genetic variants or environmental protective factors for MDS in this run.

2.4 Gene–environment interactions

Gene–environment interactions are framed largely through clonal selection: genotoxic therapy/radiation and smoking can preferentially expand clones with certain mutations (e.g., TP53, PPM1D), increasing risk of therapy-related myeloid neoplasms (zhang2024implicationsofclonal pages 2-4).

3. Phenotypes

3.1 Core clinical phenotype (symptoms/signs)

MDS clinical hallmarks include persistent cytopenias and marrow dysplasia due to ineffective hematopoiesis, typically manifesting as: - Anemia → fatigue, transfusion dependence - Neutropenia → infection susceptibility - Thrombocytopenia → bleeding/bruising These are described as the clinical consequences of ineffective hematopoiesis and cytopenias (niscola2024latestinsightsand pages 1-2).

3.2 Phenotype characteristics

• Typical onset: largely older adults (median diagnosis around ~70–75 years in clinical reviews) (nachtkamp2023myelodysplasticsyndromesnew pages 1-2, thalla2025advancesandchallenges pages 1-2)
• Severity/progression: variable; risk of AML progression depends on blast percentage, cytogenetics, and molecular profile (niscola2024latestinsightsand pages 6-7, hoff2023moleculardriversof pages 5-7)

3.3 Suggested HPO terms (examples)

(These are ontology suggestions; verify exact term IDs in HPO.) - Anemia; fatigue; dyspnea on exertion (symptom-level) - Neutropenia; recurrent infections - Thrombocytopenia; easy bruising; mucosal bleeding - Pancytopenia - Bone marrow dysplasia / ineffective hematopoiesis Supported as common cytopenic manifestations of MDS pathobiology (niscola2024latestinsightsand pages 1-2, thalla2025advancesandchallenges pages 1-2).

3.4 Quality-of-life impact

Transfusion dependence and chronic cytopenias reduce quality of life; transfusion dependence is described as being associated with reduced QoL metrics and inferior outcomes (stempel2025advancesandchallenges pages 5-7).

4. Genetic / Molecular Information

4.1 Common somatic mutation classes (current landscape)

Recurrent mutations span multiple biological programs (examples): - Epigenetic regulators: TET2, DNMT3A, ASXL1, EZH2, IDH1/2 (niscola2024latestinsightsand pages 1-2, hoff2023moleculardriversof pages 10-11) - Spliceosome: SF3B1, SRSF2, U2AF1, ZRSR2 (niscola2024latestinsightsand pages 1-2, hoff2023moleculardriversof pages 10-11) - Transcription factors / tumor suppressor: TP53, RUNX1, BCOR (niscola2024latestinsightsand pages 1-2, hoff2023moleculardriversof pages 10-11) - Cohesin complex: STAG2 (hoff2023moleculardriversof pages 10-11) - Signaling genes: NRAS/KRAS, JAK2, CBL (niscola2024latestinsightsand pages 1-2, hoff2023moleculardriversof pages 10-11)

At least one somatic mutation is reported in >90% of MDS patients (niscola2024latestinsightsand pages 6-7).

4.2 Quantitative mutation frequencies (selected examples)

• ASXL1 ~15–20% in MDS (hoff2023moleculardriversof pages 10-11)
• EZH2 ~5–10% (hoff2023moleculardriversof pages 10-11)
• TP53 ~10% de novo; higher in therapy-related disease (25%) and in del(5q) disease (20%); multi-hit TP53 predicts worse OS and AML transformation (hoff2023moleculardriversof pages 10-11)

4.3 Cytogenetic abnormalities

Common lesions include del(5q), monosomy/deletion 7, del(20q), trisomy 8, and complex karyotype (niscola2024latestinsightsand pages 1-2, karel2024myelodysplasticneoplasms(mds) pages 1-2).

4.4 Epigenetic information

MDS biology is strongly influenced by epigenetic dysregulation (DNA methylation and histone modifications), reflected by frequent mutations in epigenetic regulators (DNMT3A/TET2/ASXL1/EZH2) (niscola2024latestinsightsand pages 1-2, hoff2023moleculardriversof pages 10-11).

4.5 Suggested gene/protein ontologies (examples)

• GO biological processes (suggestions): hematopoiesis; myeloid cell differentiation; RNA splicing; DNA methylation; chromatin organization; inflammatory response.
• CL cell types (suggestions): hematopoietic stem cell; myeloid progenitor cell; erythroid progenitor; megakaryocyte.

5. Environmental Information

5.1 Environmental/lifestyle contributors

Evidence in retrieved sources supports: - Smoking as a modifiable exposure linked to clonal hematopoiesis patterns and highlighted as an addressable risk factor in burden discussions (gou2025globalregionaland pages 16-18, zhang2024implicationsofclonal pages 2-4).

5.2 Prior medical exposures

• Prior chemotherapy and radiation therapy are repeatedly flagged as risk-enhancing and are core to therapy-related myeloid neoplasms (nachtkamp2023myelodysplasticsyndromesnew pages 1-2, zhang2024implicationsofclonal pages 2-4).

5.3 Infectious agents

No evidence in retrieved sources supports a specific infectious etiology for MDS.

6. Mechanism / Pathophysiology

6.1 High-level causal chain (trigger → cellular effects → clinical phenotype)

1. Aging and/or genotoxic exposures (chemo/radiation; smoking; chronic inflammation) promote acquisition/selection of somatic mutations in HSCs (nachtkamp2023myelodysplasticsyndromesnew pages 1-2, zhang2024implicationsofclonal pages 2-4).
2. Emergence of clonal hematopoiesis (CHIP) and intermediate states such as CCUS (CHIP + persistent cytopenia), with increased risk of progression to myeloid neoplasia (testa2025clonalhematopoiesisa pages 16-18, niscola2024latestinsightsand pages 1-2).
3. Expansion of mutant clones with defects in differentiation/survival pathways produces ineffective hematopoiesis and dysplasia, causing persistent cytopenias (niscola2024latestinsightsand pages 1-2).
4. Accumulation of additional lesions (e.g., TP53 multi-hit, complex karyotype, signaling mutations) increases blasts and promotes progression to higher-risk MDS/AML (hoff2023moleculardriversof pages 10-11, hoff2023moleculardriversof pages 5-7).

6.2 Immune/inflammatory microenvironment

The marrow microenvironment is described as immune/inflammatory dysregulated, with inflammatory pathway activation contributing to clonal selection and suppression of normal hematopoiesis (niscola2024latestinsightsand pages 1-2). Mechanistically, inflammatory cytokines (e.g., TNFα, IL-6) can promote apoptosis of healthy progenitors and advantage MDS clones (baumann2025inflammatorysignalingin pages 5-7).

6.3 Molecular pathways and cellular processes (examples)

• RNA splicing dysregulation (SF3B1/SRSF2/U2AF1/ZRSR2) (niscola2024latestinsightsand pages 1-2)
• Epigenetic dysregulation (DNMT3A/TET2/ASXL1/EZH2; PRC2 biology) (hoff2023moleculardriversof pages 10-11)
• DNA damage response selection (TP53; therapy-related evolution) (zhang2024implicationsofclonal pages 2-4)

7. Anatomical Structures Affected

7.1 Organ/tissue level

• Primary site: bone marrow (hematopoietic tissue) with resulting peripheral blood cytopenias (niscola2024latestinsightsand pages 1-2, thalla2025advancesandchallenges pages 1-2)

7.2 Cell populations (suggestions)

• Hematopoietic stem and progenitor cells (HSPCs)
• Myeloid/erythroid/megakaryocytic lineages Supported by disease definition (HSC origin; multilineage dysplasia) (niscola2024latestinsightsand pages 1-2, thalla2025advancesandchallenges pages 1-2).

7.3 UBERON suggestions

• Bone marrow (UBERON term suggested; verify ID externally)

8. Temporal Development

8.1 Onset pattern

Typically insidious/chronic, diagnosed during evaluation of cytopenias, predominantly in older adults (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

8.2 Progression and staging

Progression risk is tied to blast burden, cytogenetics, and molecular lesions; WHO/ICC provide blast-based increased-blast categories and ICC introduces an MDS/AML transitional group (hoff2023moleculardriversof pages 2-4, lucero2023managementofpatients pages 1-2).

9. Inheritance and Population

9.1 Epidemiology

• Incidence: ~4 per 100,000 persons/year reported in a clinical review (nachtkamp2023myelodysplasticsyndromesnew pages 1-2); another review reports ~4 per 100,000 overall and ~25 per 100,000 among those ≥65 (thalla2025advancesandchallenges pages 1-2).
• Median age: ~70–75 years (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• Median survival: ~3 years (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

9.2 Global burden (GBD 2021-based)

A GBD analysis combining MDS/MPN reported global incidence increasing from 171,132 (1990) to 341,017 (2021) with projected incidence ~457,320 by 2045 (gou2025globalregionaland pages 1-2).

9.3 Sex/age distribution

Burden is described as higher in men and concentrated in older ages in the GBD analysis (gou2025globalregionaland pages 1-2).

9.4 Germline predisposition

Germline predisposition appears more frequent than previously appreciated, especially in younger adults (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

10. Diagnostics

10.1 Standard diagnostic workup (current practice)

• Gold standard: peripheral blood and bone marrow cytomorphology plus cytogenetics and molecular testing (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• Reviews emphasize diagnosis by cytomorphology supplemented by banding cytogenetics, histomorphology, and somatic mutation analyses (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

10.2 WHO 2022 / ICC 2022 classification diagnostics (key points)

WHO 2022/WHO-HAEM5 emphasizes genetically defined subtypes (e.g., SF3B1-mutant, biallelic TP53), retains dysplasia threshold (10%), and uses blast categories MDS-LB and MDS-IB (lucero2023managementofpatients pages 1-2, hoff2023moleculardriversof pages 2-4). ICC provides an alternative framework including an MDS/AML category for 10–19% blasts (hoff2023moleculardriversof pages 2-4, lucero2023managementofpatients pages 1-2).

Table: This table compactly aligns WHO 2022/WHO-HAEM5 and ICC 2022 blast-based MDS categories and lists key MDS-defining cytogenetic/genetic lesions. It is useful for quickly comparing category names, blast cutoffs, and the operational definition of multi-hit TP53 used in contemporary classification.

10.3 Flow cytometry

Multiparameter flow cytometry is described as a complementary diagnostic tool; it is not mandated by international baseline guidelines but is “almost universally adopted” in practice for suspected cytopenias and dysplasia detection across marrow lineages, and can support follow-up/MRD assessment (verigou2024immunophenotypingmyelodysplasticneoplasms pages 1-2).

10.4 Molecular diagnostics / genome sequencing

Modern classifications incorporate genomic profiling to define entities (e.g., SF3B1-mutant, TP53-mutant MDS) and inform prognosis via IPSS-M; this is emphasized in a 2024 Haematologica review on genome sequencing in MDS management (cazzola2024genomesequencingin pages 1-3).

10.5 Differential diagnosis (high-level)

Key differentials include CHIP/CCUS, aplastic anemia, MDS/MPN overlap entities (e.g., CMML), and AML; ICC/WHO frameworks refine boundaries and integrate genetic criteria (hoff2023moleculardriversof pages 2-4, testa2025clonalhematopoiesisa pages 16-18).

11. Outcome / Prognosis

11.1 Natural history and AML transformation

• Progression to acute leukemia occurs in ~25% in one clinical review (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• Another review states 30–40% progress to AML with poor post-transformation survival (death within ~4–6 months after transformation) (thalla2025advancesandchallenges pages 1-2).

11.2 Risk-stratified survival (IPSS-R)

Median overall survival by IPSS-R group (years): 8.8 (very low), 5.3 (low), 3.0 (intermediate), 1.6 (high), 0.8 (very high) (niscola2024latestinsightsand pages 6-7).

11.3 IPSS-M (molecular prognostication)

IPSS-M integrates clinical parameters, cytogenetics, and mutations (31 genes) and can reclassify a substantial fraction of patients (e.g., 42.5% reclassified; 29.3% upstaged in one external validation cohort) (nachtkamp2023myelodysplasticsyndromesnew pages 1-2, lee2024comparisonofthe pages 1-2).

11.4 High-risk genetic subgroup example

WHO 2022 MDS-biTP53 has markedly poor survival (median ~10 months in a reclassification study) (zhang2022comparisonofthe pages 1-2).

12. Treatment

12.1 Treatment goals (risk-adapted)

• Lower-risk MDS: reduce cytopenia burden (especially anemia), decrease transfusion dependence, improve QoL (lucero2023managementofpatients pages 1-2, stempel2025advancesandchallenges pages 5-7).
• Higher-risk MDS: prolong survival, prevent AML transformation, and pursue cure when feasible (HSCT) (kroger2024treatmentofhighrisk pages 1-2, nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

12.2 Supportive and rehabilitative care (real-world implementations)

• RBC transfusions are common (about half of patients require transfusions at diagnosis) and filtered products are recommended to reduce alloimmunization (kroger2024treatmentofhighrisk pages 1-2).
• Iron chelation: recommended after heavy transfusion exposure; one review suggests iron chelation after >20 RBC units and ferritin >2500 ng/mL with goal ferritin <1000 ng/mL (stempel2025advancesandchallenges pages 5-7); another emphasizes early deferasirox use to prevent iron overload and improve outcomes (niscola2024latestinsightsand pages 8-10).

MAXO suggestions: blood transfusion; iron chelation therapy.

12.3 ESAs (erythropoiesis-stimulating agents)

• ESA recommendation example: erythropoietin alfa for patients with endogenous EPO <200 ng/mL (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• Another review indicates practice use of ESA when EPO ≤500 mU/mL and alternatives when EPO >500 mU/mL (stempel2025advancesandchallenges pages 4-5).

MAXO suggestion: erythropoiesis-stimulating agent therapy.

12.4 Lenalidomide for del(5q) MDS

• Lenalidomide is indicated for 5q deletion (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• Reported efficacy: phase II—76% reduced transfusions and 67% achieved transfusion independence; phase III—RBC-TI 61% (10 mg) and 51.1% (5 mg) vs 7.8% placebo, with AML-free survival benefit (stempel2025advancesandchallenges pages 4-5).

MAXO suggestion: lenalidomide therapy.

12.5 Luspatercept (TGF-β superfamily ligand trap)

Phase 3 COMMANDS (2023 interim analysis; ESA-naive, transfusion-dependent LR-MDS, sEPO <500 U/L): - Primary endpoint: RBC transfusion independence ≥12 weeks plus mean Hb increase ≥1.5 g/dL during weeks 1–24. - Interim efficacy set: 86/147 (59%) luspatercept vs 48/154 (31%) epoetin alfa; risk difference 26.6% (95% CI 15.8–37.4), p<0.0001 (platzbecker2023…andsafety pages 1-2). - Longer follow-up analyses report durable benefit including ≥1 year RBC-TI 44.5% vs 27.6% (p=0.0003) (garciamanero2025longtermtransfusionindependence pages 1-2).

MAXO suggestion: luspatercept therapy.

12.6 Imetelstat (telomerase inhibitor)

IMerge phase 3 (lower-risk transfusion-dependent non-del(5q) MDS): - Primary endpoint: RBC transfusion independence ≥8 weeks. - 40% imetelstat vs 15% placebo achieved ≥8-week TI (merz2024treatmentoflowerrisk pages 3-4, fahim2024imetelstatforanemia pages 2-3). - Sustained TI ≥1 year reported 18% vs 2% (p=0.023) (fahim2024imetelstatforanemia pages 2-3). - Key grade 3/4 toxicities include neutropenia and thrombocytopenia (e.g., 68% and 62% vs 3% and 8% placebo) (fahim2024imetelstatforanemia pages 2-3).

MAXO suggestion: imetelstat therapy.

12.7 Hypomethylating agents (HMAs) and higher-risk MDS

• For higher-risk MDS patients not transplant-eligible, HMAs remain standard-of-care; azacitidine is described as the only approved non-transplant option in a 2024 Haematologica review (kroger2024treatmentofhighrisk pages 1-2).
• Azacitidine improves outcomes in higher-risk non-transplant candidates per a 2023 clinical review (nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

MAXO suggestions: azacitidine therapy; decitabine therapy.

12.8 Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Allo-HSCT is repeatedly emphasized as the only curative therapy for eligible patients, with relapse being a major cause of transplant failure (kroger2024treatmentofhighrisk pages 1-2, nachtkamp2023myelodysplasticsyndromesnew pages 1-2).

MAXO suggestion: allogeneic hematopoietic stem cell transplantation.

12.9 Targeted therapy example: IDH1 mutation (ivosidenib)

IDH1/2 mutations occur in ~5% of MDS (stempel2025advancesandchallenges pages 13-15). In IDH1-mutant MDS, ivosidenib is approved for relapsed/refractory disease with reported CR rates near 40% and median OS 35.7 months (AG120-C-001) (stempel2025advancesandchallenges pages 13-15).

MAXO suggestion: targeted small-molecule inhibitor therapy (IDH1 inhibitor).

13. Prevention

13.1 Primary prevention (risk factor modification)

• Avoidance/minimization of unnecessary genotoxic exposure (chemotherapy/radiation when alternatives exist) is conceptually supported by the association between prior cytotoxic exposure and therapy-related myeloid neoplasms and shortened time to t-MN in CH carriers (zhang2024implicationsofclonal pages 2-4, nachtkamp2023myelodysplasticsyndromesnew pages 1-2).
• Smoking cessation is supported as an addressable risk factor in burden discussions and is linked to clonal hematopoiesis selection patterns (gou2025globalregionaland pages 16-18, zhang2024implicationsofclonal pages 2-4).

13.2 Secondary prevention (early detection)

Emerging concept: monitoring high-risk CH/CCUS carriers for progression, since CH progression risk to malignancy is non-zero and measurable (e.g., ~4% over 8 years in one CH study cited in a review) (zhang2024implicationsofclonal pages 2-4). Practical implementation and validated screening programs are not established in the retrieved evidence.

13.3 Tertiary prevention

Supportive care (transfusions, iron chelation, infection management) to reduce complications of chronic cytopenias (kroger2024treatmentofhighrisk pages 1-2, stempel2025advancesandchallenges pages 5-7).

14. Other Species / Natural Disease

No tool-retrieved evidence in this run identified naturally occurring, veterinary-relevant MDS analogs with strong translational mapping.

15. Model Organisms / Experimental Systems

15.1 Human xenografts and humanized mice (current implementations)

A 2025 review summarizes that classical immunodeficient NSG/BRG mice support human HSC engraftment but poorly support myeloid/erythroid/megakaryocytic differentiation, motivating cytokine-humanized strains (munteanu2025humanizedmousemodels pages 2-3).

Key platforms: - NSG: good engraftment but limited myeloid differentiation (munteanu2025humanizedmousemodels pages 2-3). - MISTRG (human M-CSF, IL-3, GM-CSF, SIRPα, TPO): improved myeloid engraftment (>80% CD33+ reported) while preserving patient mutations (munteanu2025humanizedmousemodels pages 2-3). - NSG-SGM3 / NOG-EXL / NOGW-EXL / MISTRG6kitW41 (M6k): cytokine- and niche-engineered approaches improving lineage output and engraftment; NSG-SGM3 can have graft exhaustion and loss by ~24 weeks (munteanu2025humanizedmousemodels pages 7-7, munteanu2025humanizedmousemodels pages 5-7). - PDX models preserve genetic/phenotypic heterogeneity and can maintain mutations such as SF3B1, DNMT3A, SRSF2, TET2, TP53, RUNX1, KIT; engraftment often needs preconditioning (irradiation or macrophage depletion) and remains challenging for low-risk MDS (munteanu2025humanizedmousemodels pages 7-7, munteanu2025humanizedmousemodels pages 5-7).

15.2 Genetically engineered mouse models (GEMMs)

Examples recapitulating MDS-like features: - Runx1 deletion: anemia, trilineage dysplasia and rapid progression (munteanu2025humanizedmousemodels pages 5-7). - U2af1S34F knock-in: impaired hematopoiesis, mild dysplasia, splicing defects (munteanu2025humanizedmousemodels pages 5-7). - Ezh2 conditional knockout: impaired differentiation, dysplasia, leukemic progression (munteanu2025humanizedmousemodels pages 5-7).

15.3 Limitations (expert analysis)

No current murine model fully recapitulates the human marrow microenvironment and immune system; humanized models have limitations in long-term stability and modeling early/low-risk disease (munteanu2025humanizedmousemodels pages 1-2, munteanu2025humanizedmousemodels pages 8-10).

Expert opinions / analysis (authoritative themes)

Across contemporary reviews, expert consensus emphasizes: - Risk-adapted management integrating molecular profiling (IPSS-M, WHO/ICC genetically defined entities) (cazzola2024genomesequencingin pages 1-3, stempel2025advancesandchallenges pages 15-16). - Persistent clinical need for durable disease-modifying therapies, particularly for high-risk genomics (e.g., multi-hit TP53) where outcomes remain poor (stempel2025advancesandchallenges pages 13-15, zhang2022comparisonofthe pages 1-2). - Pragmatic multimodality diagnostics: morphology remains essential but is subjective; genomic and cytogenetic data increasingly define entities; flow cytometry is widely used as a complement (vicente2024whoiccclassificationfor pages 1-2, verigou2024immunophenotypingmyelodysplasticneoplasms pages 1-2).

Key recent developments (prioritized 2023–2024)

1. Classification modernization: WHO 2022/WHO-HAEM5 and ICC 2022 incorporate genetically defined entities (SF3B1-mutant, biallelic TP53) and refine blast-based categories (hoff2023moleculardriversof pages 2-4, lucero2023managementofpatients pages 1-2).
2. Frontline anemia therapy shift (2023): COMMANDS showed luspatercept superiority over epoetin alfa for a composite transfusion/Hb endpoint in ESA-naive LR-MDS (platzbecker2023…andsafety pages 1-2, merz2024treatmentoflowerrisk pages 3-4).
3. Molecular diagnostics and precision medicine (2024): genome sequencing reviews emphasize molecular taxonomy and IPSS-M integration into decision-making (cazzola2024genomesequencingin pages 1-3).

Notes on citation requirements (PMID limitation)

Many retrieved sources are journal articles with DOIs but PMIDs were not available in the extracted tool evidence; therefore, this report cites the retrieved sources via tool citation IDs, and provides URLs/DOIs (embedded in the evidence metadata). For a production knowledge base, PMIDs should be added by cross-referencing these DOIs in PubMed.

References

1. (lucero2023managementofpatients pages 1-2): Josephine Lucero, Salman Al-Harbi, and Karen W. L. Yee. Management of patients with lower-risk myelodysplastic neoplasms (mds). Current Oncology, 30:6177-6196, Jun 2023. URL: https://doi.org/10.3390/curroncol30070459, doi:10.3390/curroncol30070459. This article has 7 citations.

2. (niscola2024latestinsightsand pages 1-2): Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone, and Paolo de Fabritiis. Latest insights and therapeutic advances in myelodysplastic neoplasms. Cancers, 16:1563, Apr 2024. URL: https://doi.org/10.3390/cancers16081563, doi:10.3390/cancers16081563. This article has 13 citations.

3. (thalla2025advancesandchallenges pages 1-2): Rohit Thalla, Ryan Mack, Jorgena Kosti-Schwartz, Peter Breslin, and Jiwang Zhang. Advances and challenges in the treatment of myelodysplastic syndromes. Experimental Hematology & Oncology, Jun 2025. URL: https://doi.org/10.1186/s40164-025-00678-9, doi:10.1186/s40164-025-00678-9. This article has 8 citations and is from a peer-reviewed journal.

4. (gou2025globalregionaland pages 2-3): Xinyue Gou, Zhuo Chen, and Yudi Shangguan. Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021. Frontiers in Oncology, Mar 2025. URL: https://doi.org/10.3389/fonc.2025.1559382, doi:10.3389/fonc.2025.1559382. This article has 10 citations.

5. (zhang2022comparisonofthe pages 1-2): Yudi Zhang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Huijun Wang, Peihong Zhang, Xin Yan, Jingye Gong, Qingyan Gao, Robert Peter Gale, and Zhijian Xiao. Comparison of the revised 4th (2016) and 5th (2022) editions of the world health organization classification of myelodysplastic neoplasms. Leukemia, 36:2875-2882, Oct 2022. URL: https://doi.org/10.1038/s41375-022-01718-7, doi:10.1038/s41375-022-01718-7. This article has 76 citations and is from a highest quality peer-reviewed journal.

6. (platzbecker2023…andsafety pages 1-2): U Platzbecker, MG Della Porta, V Santini, and AM Zeidan. … and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (commands) …. Unknown journal, 2023.

7. (gou2025globalregionaland pages 1-2): Xinyue Gou, Zhuo Chen, and Yudi Shangguan. Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021. Frontiers in Oncology, Mar 2025. URL: https://doi.org/10.3389/fonc.2025.1559382, doi:10.3389/fonc.2025.1559382. This article has 10 citations.

8. (karel2024myelodysplasticneoplasms(mds) pages 1-2): Daniel Karel, Claire Valburg, Navitha Woddor, Victor E. Nava, and Anita Aggarwal. Myelodysplastic neoplasms (mds): the current and future treatment landscape. Current Oncology, 31:1971-1993, Apr 2024. URL: https://doi.org/10.3390/curroncol31040148, doi:10.3390/curroncol31040148. This article has 19 citations.

9. (nachtkamp2023myelodysplasticsyndromesnew pages 1-2): Kathrin Nachtkamp, Guido Kobbe, Norbert Gattermann, and Ulrich Germing. Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment. Deutsches Ärzteblatt international, Mar 2023. URL: https://doi.org/10.3238/arztebl.m2023.0005, doi:10.3238/arztebl.m2023.0005. This article has 31 citations.

10. (zhang2024implicationsofclonal pages 2-4): Qi Zhang, Rita Yim, Paul Lee, Lynn Chin, Vivian Li, and Harinder Gill. Implications of clonal hematopoiesis in hematological and non-hematological disorders. Cancers, 16:4118, Dec 2024. URL: https://doi.org/10.3390/cancers16234118, doi:10.3390/cancers16234118. This article has 5 citations.

11. (niscola2024latestinsightsand pages 6-7): Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone, and Paolo de Fabritiis. Latest insights and therapeutic advances in myelodysplastic neoplasms. Cancers, 16:1563, Apr 2024. URL: https://doi.org/10.3390/cancers16081563, doi:10.3390/cancers16081563. This article has 13 citations.

12. (hoff2023moleculardriversof pages 5-7): Fieke W. Hoff and Yazan F. Madanat. Molecular drivers of myelodysplastic neoplasms (mds)—classification and prognostic relevance. Cells, 12:627, Feb 2023. URL: https://doi.org/10.3390/cells12040627, doi:10.3390/cells12040627. This article has 16 citations.

13. (stempel2025advancesandchallenges pages 5-7): J. Stempel, Tariq Kewan, and A. Zeidan. Advances and challenges in the management of myelodysplastic syndromes. Cancers, Jul 2025. URL: https://doi.org/10.3390/cancers17152469, doi:10.3390/cancers17152469. This article has 6 citations.

14. (hoff2023moleculardriversof pages 10-11): Fieke W. Hoff and Yazan F. Madanat. Molecular drivers of myelodysplastic neoplasms (mds)—classification and prognostic relevance. Cells, 12:627, Feb 2023. URL: https://doi.org/10.3390/cells12040627, doi:10.3390/cells12040627. This article has 16 citations.

15. (gou2025globalregionaland pages 16-18): Xinyue Gou, Zhuo Chen, and Yudi Shangguan. Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021. Frontiers in Oncology, Mar 2025. URL: https://doi.org/10.3389/fonc.2025.1559382, doi:10.3389/fonc.2025.1559382. This article has 10 citations.

16. (testa2025clonalhematopoiesisa pages 16-18): Ugo Testa, Germana Castelli, and Elvira Pelosi. Clonal hematopoiesis, a risk condition for developing myeloid neoplasia. Hemato, 6:10, Apr 2025. URL: https://doi.org/10.3390/hemato6020010, doi:10.3390/hemato6020010. This article has 3 citations.

17. (baumann2025inflammatorysignalingin pages 5-7): Artemis Margrith Baumann and Jana Maria Ellegast. Inflammatory signaling in the pathogenesis of acute myeloid leukemia. HemaSphere, Aug 2025. URL: https://doi.org/10.1002/hem3.70188, doi:10.1002/hem3.70188. This article has 6 citations and is from a peer-reviewed journal.

18. (hoff2023moleculardriversof pages 2-4): Fieke W. Hoff and Yazan F. Madanat. Molecular drivers of myelodysplastic neoplasms (mds)—classification and prognostic relevance. Cells, 12:627, Feb 2023. URL: https://doi.org/10.3390/cells12040627, doi:10.3390/cells12040627. This article has 16 citations.

19. (lee2024comparisonofthe pages 1-2): Wan-Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, Feng-Ming Tien, Min-Yen Lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Shan-Chi Yu, Ming-Chih Liu, Chang-Tsu Yuan, Yi-Tsung Yang, Ming-Kai Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Yi-Kuang Chuang, Hwei-Fang Tien, Hsin-An Hou, and Wen-Chien Chou. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms. Blood Cancer Journal, Apr 2024. URL: https://doi.org/10.1038/s41408-024-01031-9, doi:10.1038/s41408-024-01031-9. This article has 33 citations and is from a domain leading peer-reviewed journal.

20. (lapadat2025navigatingthenew pages 2-4): Mihai-Emilian Lapadat, Oana Stanca, Nicoleta Mariana Berbec, Cristina Negotei, and Andrei Colita. Navigating the new era in myelodysplastic neoplasms: a review of prognostic implications of the ipss-m score and 2022 who classification. Hematology Reports, 17:58, Oct 2025. URL: https://doi.org/10.3390/hematolrep17060058, doi:10.3390/hematolrep17060058. This article has 3 citations.

21. (niscola2024latestinsightsand pages 4-6): Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone, and Paolo de Fabritiis. Latest insights and therapeutic advances in myelodysplastic neoplasms. Cancers, 16:1563, Apr 2024. URL: https://doi.org/10.3390/cancers16081563, doi:10.3390/cancers16081563. This article has 13 citations.

22. (abdulbaki2024abriefoverview pages 3-4): Rami Abdulbaki and Sheeja T. Pullarkat. A brief overview of the molecular landscape of myelodysplastic neoplasms. Current Oncology, 31:2353-2363, Apr 2024. URL: https://doi.org/10.3390/curroncol31050175, doi:10.3390/curroncol31050175. This article has 8 citations.

23. (verigou2024immunophenotypingmyelodysplasticneoplasms pages 1-2): Evgenia Verigou, Theodora Chatzilygeroudi, Vasileios Lazaris, Anne-Lise de Lastic, and Argiris Symeonidis. Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era. Frontiers in Oncology, Oct 2024. URL: https://doi.org/10.3389/fonc.2024.1447001, doi:10.3389/fonc.2024.1447001. This article has 10 citations.

24. (cazzola2024genomesequencingin pages 1-3): Mario Cazzola and Luca Malcovati. Genome sequencing in the management of myelodysplastic syndromes and related disorders. Haematologica, 110:312-329, Oct 2024. URL: https://doi.org/10.3324/haematol.2023.284947, doi:10.3324/haematol.2023.284947. This article has 13 citations.

25. (kroger2024treatmentofhighrisk pages 1-2): Nicolaus Kröger. Treatment of high-risk myelodysplastic syndromes. Haematologica, 110:339-349, Dec 2024. URL: https://doi.org/10.3324/haematol.2023.284946, doi:10.3324/haematol.2023.284946. This article has 39 citations.

26. (niscola2024latestinsightsand pages 8-10): Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone, and Paolo de Fabritiis. Latest insights and therapeutic advances in myelodysplastic neoplasms. Cancers, 16:1563, Apr 2024. URL: https://doi.org/10.3390/cancers16081563, doi:10.3390/cancers16081563. This article has 13 citations.

27. (stempel2025advancesandchallenges pages 4-5): J. Stempel, Tariq Kewan, and A. Zeidan. Advances and challenges in the management of myelodysplastic syndromes. Cancers, Jul 2025. URL: https://doi.org/10.3390/cancers17152469, doi:10.3390/cancers17152469. This article has 6 citations.

28. (garciamanero2025longtermtransfusionindependence pages 1-2): Guillermo Garcia-Manero, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Veronika Pozharskaya, Shelonitda Rose, Karen Keeperman, Yinzhi Lai, Sameer Kalsekar, Barkha Aggarwal, Dimana Miteva, David Valcárcel, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta, and Uwe Platzbecker. Long-term transfusion independence with luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, lower-risk myelodysplastic syndromes in the commands trial. Advances in Therapy, 42:3576-3589, May 2025. URL: https://doi.org/10.1007/s12325-025-03208-5, doi:10.1007/s12325-025-03208-5. This article has 8 citations and is from a peer-reviewed journal.

29. (merz2024treatmentoflowerrisk pages 3-4): Almuth Maria Anni Merz and Uwe Platzbecker. Treatment of lower-risk myelodysplastic syndromes. Haematologica, 110:330-338, Oct 2024. URL: https://doi.org/10.3324/haematol.2023.284945, doi:10.3324/haematol.2023.284945. This article has 17 citations.

30. (fahim2024imetelstatforanemia pages 2-3): Shahariar Mohammed Fahim, Jeffrey A. Tice, Linda Luu, Josh J. Carlson, Marina Richardson, Belen Herce-Hagiwara, Ronald Dickerson, and Daniel A. Ollendorf. Imetelstat for anemia in lower-risk myelodysplastic syndromes: a summary from the institute for clinical and economic review's california technology assessment forum. Journal of managed care & specialty pharmacy, 30 12:1479-1485, Dec 2024. URL: https://doi.org/10.18553/jmcp.2024.30.12.1479, doi:10.18553/jmcp.2024.30.12.1479. This article has 0 citations.

31. (stempel2025advancesandchallenges pages 13-15): J. Stempel, Tariq Kewan, and A. Zeidan. Advances and challenges in the management of myelodysplastic syndromes. Cancers, Jul 2025. URL: https://doi.org/10.3390/cancers17152469, doi:10.3390/cancers17152469. This article has 6 citations.

32. (munteanu2025humanizedmousemodels pages 2-3): R. Munteanu, Diana Gulei, C. Moldovan, Emanuele Azzoni, Laura Belver, Richard-Ionut Feder, Simina Pîrv, A. Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert P Hasserjian, and C. Tomuleasa. Humanized mouse models in mds. Cell Death & Disease, Jul 2025. URL: https://doi.org/10.1038/s41419-025-07861-0, doi:10.1038/s41419-025-07861-0. This article has 4 citations and is from a peer-reviewed journal.

33. (munteanu2025humanizedmousemodels pages 7-7): R. Munteanu, Diana Gulei, C. Moldovan, Emanuele Azzoni, Laura Belver, Richard-Ionut Feder, Simina Pîrv, A. Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert P Hasserjian, and C. Tomuleasa. Humanized mouse models in mds. Cell Death & Disease, Jul 2025. URL: https://doi.org/10.1038/s41419-025-07861-0, doi:10.1038/s41419-025-07861-0. This article has 4 citations and is from a peer-reviewed journal.

34. (munteanu2025humanizedmousemodels pages 5-7): R. Munteanu, Diana Gulei, C. Moldovan, Emanuele Azzoni, Laura Belver, Richard-Ionut Feder, Simina Pîrv, A. Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert P Hasserjian, and C. Tomuleasa. Humanized mouse models in mds. Cell Death & Disease, Jul 2025. URL: https://doi.org/10.1038/s41419-025-07861-0, doi:10.1038/s41419-025-07861-0. This article has 4 citations and is from a peer-reviewed journal.

35. (munteanu2025humanizedmousemodels pages 1-2): R. Munteanu, Diana Gulei, C. Moldovan, Emanuele Azzoni, Laura Belver, Richard-Ionut Feder, Simina Pîrv, A. Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert P Hasserjian, and C. Tomuleasa. Humanized mouse models in mds. Cell Death & Disease, Jul 2025. URL: https://doi.org/10.1038/s41419-025-07861-0, doi:10.1038/s41419-025-07861-0. This article has 4 citations and is from a peer-reviewed journal.

36. (munteanu2025humanizedmousemodels pages 8-10): R. Munteanu, Diana Gulei, C. Moldovan, Emanuele Azzoni, Laura Belver, Richard-Ionut Feder, Simina Pîrv, A. Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert P Hasserjian, and C. Tomuleasa. Humanized mouse models in mds. Cell Death & Disease, Jul 2025. URL: https://doi.org/10.1038/s41419-025-07861-0, doi:10.1038/s41419-025-07861-0. This article has 4 citations and is from a peer-reviewed journal.

37. (stempel2025advancesandchallenges pages 15-16): J. Stempel, Tariq Kewan, and A. Zeidan. Advances and challenges in the management of myelodysplastic syndromes. Cancers, Jul 2025. URL: https://doi.org/10.3390/cancers17152469, doi:10.3390/cancers17152469. This article has 6 citations.

38. (vicente2024whoiccclassificationfor pages 1-2): Ana Isabel Vicente, Irene Luna, Juan Carlos Ruiz, María José Remigia, Andrés Jerez, Rafael Lluch, Inmaculada Llopis, María Josefa Marco, Carmen Benet, Carmen Alonso, María Dolores Linares, Luis Serrano, María Teresa Orero, Francisco José Ortuño, and María Leonor Senent. Who/icc classification for myelodysplastic neoplasms/syndromes performs better for subtype cytomorphological diagnosis? Diagnostics, 14:1631, Jul 2024. URL: https://doi.org/10.3390/diagnostics14151631, doi:10.3390/diagnostics14151631. This article has 2 citations.

Artifacts

• Edison artifact artifact-00